I
Icosavax
Developing safe and effective vaccines against infectious diseases that cause severe, life-threatening respiratory illnesses
About Icosavax
Icosavax, founded in 2017, is a clinical-stage biotechnology company focused on developing vaccines to protect vulnerable older adults from severe respiratory infections. The company leverages a novel approach using virus-like particles (VLPs) that mimic the structure of viruses to elicit a stronger immune response. Icosavax operates in the biotechnology and healthcare market, primarily serving older adults who are at higher risk for respiratory diseases. The company's business model involves the discovery, development, and commercialization of VLP-based vaccines. Revenue is generated through partnerships, licensing agreements, and eventual vaccine sales. As a member of the AstraZeneca Group, Icosavax benefits from extensive resources and expertise in the pharmaceutical industry.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2018
- Headquarters
- Seattle, United States
- Listing
- IPO 2021
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 62.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Vaccines, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2023 | $1.1B | $1.1B | AstraZeneca | ↗ |
| POST IPO EQUITYOther financing | May 2023 | $68M | — | Vivo Capital · TCGX · Logos Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $1M | 0% | −$95M | -9505.8% |
| 2025 | $1M | -33.3% | −$95M | -9505.8% |
| 2024 | $1.5M | +200% | −$95M | -6337.2% |
| 2023 | $500K | — | −$95M | -19011.6% |
| 2022 | $0 | — | −$95M | — |
| 2021 | $0 | — | −$65M | — |
| 2020 | $0 | — | −$19M | — |
Growth signals
Latest recorded traffic for Icosavax is 770 monthly website visits, down 45% over the last three months. Icosavax's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Bill & Melinda Gates Foundation
Open Philanthropy Project
Series A11 investors entered at this stage
Qiming Venture Partners USA
RA Capital Management
Adams Street Partners
Citadel
Cormorant Asset Management
+ND Capital
Omega Funds
Viking Global Investors
Janus Henderson Investors
Sanofi Ventures
Perceptive Advisors
Series B and later3 investors entered at this stage
Vivo Capital
TCGX
Logos Capital
Other known investors3 additional known investors
AstraZeneca
University of Washington
University of Washington Institute for Protein Design
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Icosavax on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Icosavax’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.